الفهرس | Only 14 pages are availabe for public view |
Abstract The non-hodgkin`s lymphomas (nhls) are a collection of lymphoid malignancies with a diverse pathology and natural history. nhls despite being initially chemosensitive, they become eventually refractory. multidrug resistance (mdr) is the protection of a tumor cell population against numerous drugs differing in chemical structure and mechanisms of influence on the cells. it is still unclear whether overexpression of mdr-1 gene plays a role in the chemotherapy resistance in lymphoma. this study was designed to assess p-gp expression in lymphoma patients and to observe the impact effect of p-gp level upon chemotherapy response. in this study we assessed the expression of mdr-1 in 29 patients with nhl using monoclonal antibodies by flowcytometric method. we found that: 1- there is non significant difference in the frequency of p-gp expression regarding the age and the gender. 2- there is a significant increase in ldh and decrease in hb level in the relapsed nhl group when compared with both de novo and the control group. 3- there is increased expression of p-gp in non-hodgkin’s lymphoma more than the control group. 4- p-gp expression is higher in relapsed nhl than nhl at diagnosis (de novo). 5- there is non significant difference in the frequency of p-gp expression regarding different pathological types. meanwhile, there was significant increase in the level of mdr-1 expression in the high grade nhl patients when compared with both low and intermediate grades. 6- there is non significant difference in frequency of p-gp expression regarding different stages. meanwhile, there was significant increase in mdr-1 expression in stage iii and iv compared with stage ii with non significant difference in mdr-1 expression between stage iii and iv. 7- patients with positive mdr-1 expression have higher incidence of resistance to chemotherapy and failure to achieve complete remission, than patients with negative mdr-1. |